Cyclophosphamide_plus_cisplatin_versus_cyclophosphamide,_doxorubicin,_and_cisplatin_chemotherapy_of_ovarian_carcinoma:_a_meta-analysis._The_Ovarian_Cancer_Meta-Analysis_Project._Four_randomized_clinical_trials_comparing_cyclophosphamide_plus_cisplatin_(CP)_versus_cyclophosphamide,_doxorubicin,_and_cisplatin_(CAP)_individually_failed_to_show_a_significant_survival_difference_in_the_treatment_of_ovarian_carcinoma._However,_by_pooling_1,194_patients_from_these_trials_in_a_meta-analysis,_there_is_a_statistically_significant_survival_benefit_for_CAP_(P_=_.02);_in_addition,_there_is_a_significant_advantage_for_CAP_in_frequency_of_negative_second-look_laparotomy_(CAP,_30%;_CP,_23%;_P_=_.01)._Because_the_dose_intensity_of_CAP_was_greater_than_CP_in_three_of_the_trials,_it_remains_unresolved_to_what_extent_the_benefit_of_CAP_is_from_greater_dose_intensity_and_to_what_extent_it_is_from_the_doxorubicin_itself._Either_interpretation_suggests_directions_for_improving_the_chemotherapy_of_ovarian_carcinoma.